Nuvation Bio Inc. – NYSE:NUVB

Add to watchlist

$2.74

-0.01

-0.72%

Market closed

Open in about 12 hours

-20.23%

month

-20.23%

quarter

+80.39%

year

Market Cap	881.80M
Enterprise value	280.25M

P/E	-3.48
EV/Sales	N/A
EV/EBITDA	-1.78
Price/Sales	N/A
Price/Book	0.57
PEG ratio	0.38
EPS	-0.31

Revenue	N/A
EBITDA	-93.30M
Income	-68.86M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nuvation Bio Inc. (NYSE:NUVB): Profit margin
Jun 2023	0	-20.64M
Sep 2023	0	-19.64M
Dec 2023	264K	-13.78M	-5222.35%
Mar 2024	0	-14.79M

Nuvation Bio Financials Estimate

Q Y

Nuvation Bio Inc. (NYSE:NUVB): Analyst Estimates
Mar 2024	0	-14.79M
Sep 2025	264K	-29.56M	-11198.51%
Oct 2025	0	-25.24M
Dec 2025	0	-27.54M

Analysts Price target
Financials & Ratios estimates

Nuvation Bio Inc. (NYSE:NUVB): Debt to assets
Jun 2023	641410000	16.77M	2.62%
Sep 2023	630870000	19.28M	3.06%
Dec 2023	621484000	16.36M	2.63%
Mar 2024	613125000	19.08M	3.11%

Nuvation Bio Inc. (NYSE:NUVB): Cash Flow
Jun 2023	-17.48M	37.34M	133K
Sep 2023	-16.15M	-9.59M	77K
Dec 2023	-15.02M	33.16M	120K
Mar 2024	-15.70M	7.54M	21K

Nuvation Bio alternative data

Nuvation Bio Inc. (NYSE:NUVB): Employee count
Aug 2023	53
Sep 2023	54
Oct 2023	54
Nov 2023	54
Dec 2023	53
Jan 2024	53
Feb 2024	53
Mar 2024	51
Apr 2024	51
May 2024	51
Jun 2024	159
Jul 2024	159

Nuvation Bio
Hedge Funds Holdings Q3 2022

100.00% 0.00%

of NUVB is owned by hedge funds

109 -7

hedge funds hold NUVB stock

137.40M -17.89M

shares is hold by hedge funds

NUVB hedge funds holdings changes

Nuvation Bio Inc. (NYSE:NUVB): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	5313100	0
Jun 2024	172189	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	11 Jun 2024	BLICKENSTAFF KIM D director director	Class A Common Stock	172,189	$2.9	$500,037
Option	24 May 2024	WELCH DANIEL G director director	Class A Common Stock	366,744	$1.64	$601,460
Option	24 May 2024	WELCH DANIEL G director director	Class A Common Stock	293,203	$1.74	$510,173
Option	24 May 2024	WELCH DANIEL G director director	Stock Option (Right to Buy)	293,203	$1.74	$510,173
Option	24 May 2024	WELCH DANIEL G director director	Stock Option (Right to Buy)	366,744	$1.64	$601,460
Purchase	21 Sep 2023	NODELMAN OLEG director director	Class A Common Stock	53,000	$1.36	$72,133
Purchase	20 Sep 2023	NODELMAN OLEG director director	Class A Common Stock	117,100	$1.36	$159,490
Purchase	19 Sep 2023	NODELMAN OLEG director director	Class A Common Stock	5,143,000	$1.26	$6,459,608
Purchase	5 Dec 2022	FALBERG KATHRYN E director director	Class A Common Stock	43,000	$1.95	$83,979
Purchase	2 Dec 2022	FALBERG KATHRYN E director director	Class A Common Stock	47,000	$1.98	$93,201

Status	Patent	Filling date	Issue date
Application	Application HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Filling date: 13 Aug 2020 Issue date: 8 Sep 2022	13 Aug 2020	8 Sep 2022
Application	Application HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Filling date: 1 Jul 2020 Issue date: 1 Sep 2022	1 Jul 2020	1 Sep 2022
Application	Application CRYSTALLINE FORMS OF A CYCLIN-DEPENDENT KINASE INHIBITOR Filling date: 2 Feb 2022 Issue date: 18 Aug 2022	2 Feb 2022	18 Aug 2022
Application	Application HETEROCYCLIC COMPOUNDS AND USES THEREOF Filling date: 8 Apr 2020 Issue date: 14 Jul 2022	8 Apr 2020	14 Jul 2022
Application	Application SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS Filling date: 2 Dec 2021 Issue date: 7 Jul 2022	2 Dec 2021	7 Jul 2022
Application	Application 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF Filling date: 18 Feb 2022 Issue date: 2 Jun 2022	18 Feb 2022	2 Jun 2022
Application	Application HETEROCYCLIC COMPOUNDS AND USES THEREOF Filling date: 8 Apr 2020 Issue date: 2 Jun 2022	8 Apr 2020	2 Jun 2022
Application	Application HETEROCYCLIC COMPOUNDS AND USES THEREOF Filling date: 8 Apr 2020 Issue date: 2 Jun 2022	8 Apr 2020	2 Jun 2022
Application	Application HETEROCYCLIC COMPOUNDS AND USES THEREOF Filling date: 8 Apr 2020 Issue date: 26 May 2022	8 Apr 2020	26 May 2022
Application	Application HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS Filling date: 17 Jan 2020 Issue date: 21 Apr 2022	17 Jan 2020	21 Apr 2022

Nuvation Bio
Executives

Insider	Age	Compensation
Dr. David T. Hung M.D. (1958) Founder, Pres, Chief Executive Officer & Director	67	$1,160,000
Dr. Gary Hattersley Ph.D. (1967) Chief Scientific Officer	58	$687,880
Ms. Jennifer A. Fox (1972) Chief Financial Officer	53	$557,900

Nuvation Bio
Latest News

Monday, 23 December 2024
08:00	U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer	businesswire.com
Friday, 20 December 2024
07:10	Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration	prnewswire.com
Tuesday, 26 November 2024
08:00	Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference	businesswire.com
Monday, 7 October 2024
16:05	Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer	businesswire.com
Saturday, 14 September 2024
03:05	Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024	businesswire.com
Monday, 9 September 2024
08:00	Nuvation Bio to Present at the Cantor Global Healthcare Conference	businesswire.com
Tuesday, 23 July 2024
16:05	Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib	businesswire.com
Sunday, 2 June 2024
01:13	Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting	prnewswire.com
Saturday, 1 June 2024
20:00	Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting	prnewswire.com
08:10	Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting	businesswire.com
Wednesday, 29 May 2024
16:05	Nuvation Bio to Present at the Jefferies Global Healthcare Conference	businesswire.com
Tuesday, 14 May 2024
16:05	Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update	businesswire.com
Wednesday, 24 April 2024
10:01	Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Business Wire
Sunday, 31 March 2024
10:00	Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate	Seeking Alpha
Friday, 8 March 2024
13:01	Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know	Zacks Investment Research
Saturday, 18 March 2023
18:48	The 7 Worst Stocks to Buy Now	InvestorPlace
Monday, 27 June 2022
09:08	FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why	Benzinga
Friday, 21 January 2022
11:35	Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate	Zacks Investment Research
Thursday, 20 January 2022
08:43	FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors	Benzinga
Monday, 13 December 2021
12:01	Why Nuvation Bio Shares Are Rising	Benzinga

Ideas & Opinions

Seeking Alpha 18 Jun 2025

Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements
Seeking Alpha 7 May 2025

Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes
Seeking Alpha 31 Mar 2024

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Seeking Alpha 31 Mar 2024

Week In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Deal
Seeking Alpha 3 Oct 2023

Nuvation: Cash Is King, Science Is An Afterthought

Frequently Asked Questions (FAQ)

What's the price of Nuvation Bio stock today?

One share of Nuvation Bio stock can currently be purchased for approximately $2.74.
When is Nuvation Bio's next earnings date?

Unfortunately, Nuvation Bio's (NUVB) next earnings date is currently unknown.
Does Nuvation Bio pay dividends?

No, Nuvation Bio does not pay dividends.
How much money does Nuvation Bio make?

Nuvation Bio has a market capitalization of 881.80M.
What is Nuvation Bio's stock symbol?

Nuvation Bio Inc. is traded on the NYSE under the ticker symbol "NUVB".
What is Nuvation Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nuvation Bio?

Shares of Nuvation Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Nuvation Bio's key executives?
Nuvation Bio's management team includes the following people:
- Dr. David T. Hung M.D. Founder, Pres, Chief Executive Officer & Director(age: 67, pay: $1,160,000)
- Dr. Gary Hattersley Ph.D. Chief Scientific Officer(age: 58, pay: $687,880)
- Ms. Jennifer A. Fox Chief Financial Officer(age: 53, pay: $557,900)
Is Nuvation Bio founder-led company?

Yes, Nuvation Bio is a company led by its founder Dr. David T. Hung M.D..
How many employees does Nuvation Bio have?

As Jul 2024, Nuvation Bio employs 159 workers, which is 212% more then previous quarter.
When Nuvation Bio went public?

Nuvation Bio Inc. is publicly traded company for more then 5 years since IPO on 26 Aug 2020.
What is Nuvation Bio's official website?

The official website for Nuvation Bio is nuvationbio.com.
Where are Nuvation Bio's headquarters?

Nuvation Bio is headquartered at 1500 Broadway, New York, NY.
How can i contact Nuvation Bio?

Nuvation Bio's mailing address is 1500 Broadway, New York, NY and company can be reached via phone at +33 22086102.

Nuvation Bio Inc.

nuvationbio.com

Exchange:

NYSE

Full time employees:

203

Industry:

Biotechnology

Sector:

Healthcare

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

+33 22086102

1500 Broadway
New York, NY 10036

CIK: 0001811063
ISIN: US67080N1019
CUSIP: 67080N101